Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To monitor residual risks in the post-market phase and to ensure continued clinical evaluation of the device safety and performance to ensure that no new or unexpected risks arise when used during multi-ligament knee reconstructions.
OrthoPureXT is an acellular, sterile, single use, xenograft (porcine) tissue scaffold that is manufactured using a proprietary decellularisation technology that renders the tissue substantially free from cells, leaving the porcine tissue biocompatible, and safe for implantation into the knee.
28 patients in total to be evenly distributed across potential ligament reconstruction treatment options (n=7 per sub-group) and resulting in a statistically relevant number per sub-group considering potential loss to follow up.
Sub-groups of n=7 incurring ligament reconstruction using OrthoPure XT in the following anatomical locations:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Multiple Knee Ligament Injuries | Experimental | Sub-groups of n=7 incurring ligament reconstruction using OrthoPureXT in the following anatomical locations:
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| OrthoPure XT | Device | Indication: reconstruction of knee ligaments to restore knee function and stability The following device sizes are available for use in this indication:
|
| Measure | Description | Time Frame |
|---|---|---|
| A change from Baseline in IKDC | Assessment of knee stability via evaluation of IKDC score. | Baseline (30 days prior to surgery); 1, 3, 6 months after surgery (normal clinical follow-up); 12 and 24 months after surgery (long term follow-up) |
| Measure | Description | Time Frame |
|---|---|---|
| A change from Baseline in Lysholm | Assessment of knee stability via evaluation of Lysholm score. | Baseline (30 days prior to surgery); 1, 3 ,6 months after surgery (normal clinical follow-up); 12 and 24 months after surgery (long term follow-up) |
| A change from Baseline in KOOS |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Those unable to give consent.
Those considered as conflicting variables by the investigator. This may include, but is not limited to:
Those considered as physical barriers by the investigator, preventing physical or ethical collection of study data. This may include, but is not limited to:
Those considered as a poor candidate for surgery by the investigator.
If female and of child-bearing potential must not have a positive pregnancy test at Visit
1 nor have a stated intention to become pregnant in the next 12 months.
Those patients contraindicated for in the IFU, i.e.:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Anna Kaniewska | Contact | +44 (0)3304303052 | a.kaniewska@tissueregenix.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royal Stoke University Hospital | Recruiting | Stoke-on-Trent | ST4 6QG | United Kingdom |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007718 | Knee Injuries |
| ID | Term |
|---|---|
| D007869 | Leg Injuries |
| D014947 | Wounds and Injuries |
Not provided
Not provided
Subjects with multiligament knee injuries will be evenly distributed across potential ligament reconstruction treatment options: PCL, ACL, MCL, LCL.
Not provided
Not provided
Not provided
Not provided
|
Assessment of knee stability via evaluation of KOOS. |
| Baseline (30 days prior to surgery); 1, 3, 6 months after surgery (normal clinical follow-up); 12 and 24 months after surgery (long term follow-up) |
| A change from Baseline in Assessment of Laxity via Physical Examination | Physical assessment of passive movement focusing on the reconstructed ligament. | Baseline (30 days prior to surgery); 1, 3, 6 months after surgery (normal clinical follow-up); 12 and 24 months after surgery (long term follow-up) |